A Randomized, Double-Blind, Placebo-Controlled Study of COR388 HCl in Subjects With Alzheimer's Disease
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 05 Feb 2019
At a glance
- Drugs COR-388 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Cortexyme
- 27 Sep 2018 According to a Cortexyme media release, the company has announced the formation of a new Clinical Advisory Board (CAB) in preparation for starting Phase II clinical development in Alzheimer's disease next year.
- 07 Jun 2018 New trial record
- 31 May 2018 According to a Cortexyme media release, the company is planning to initiate this study next year.